John Parkinson

The rise of multidrug-resistant gonorrhea highlights the urgent need for new therapies. Zoliflodacin, a promising oral antibiotic, shows effectiveness in late-stage trials.

A new survey finds that 61% of infectious disease professionals identify mosquito-borne viruses, like dengue and Zika, as the greatest threat posed by climate change, demanding global action.

The CDC and the National Foundation for Infectious Diseases (NFID) discuss the evolving summer COVID-19 season and strategies for prevention.

Colorado reports that the transmission source has not yet been identified.

Research findings reveal that correcting misinformation about vaccination can remarkably transform individuals' attitudes toward it. This highlights the crucial role of accurate information in making informed decisions about vaccination.

Ten cases of measles have been reported Florida alone. With measles transmission rates soaring, questions abound about how this latest case emerged, and why these numbers keep rising.

According to a recent study, bleach fails to eradicate C difficile spores in hospital scrubs, raising concerns about disinfectant efficacy and bacterial resistance in health care settings.

BiomX Develops BX004-A, a Phage Therapy, for Cystic Fibrosis Patients with Pseudomonas Infections. A phase 1b/2a study presents promising results at IDWeek 2023.

Hepatitis C cases increased in 2021, while A and B decreased. The pandemic may have impacted the progress.

A small study explored the connection between Postural Orthostatic Tachycardia Syndrome (POTS) and the COVID-19 condition.

Vaccitech, a biopharmaceutical company, has created a vaccine named VTP-300. They are currently showcasing positive initial results through a poster presentation at the ongoing European Association for the Study of the Liver (EASL) Congress 2023.

Trade name Xacduro is an antibiotic meant to treat hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by Acinetobacter baumannii.

Prescribers are presented with the optimal therapy challenges and achieving antibacterial stewardship.

With the focus of COVID-19, MRSA infections increased. How did the VA work to prevent this pathogen?

Despite the recent CDC warning and frightening media coverage, understanding which patients are at a higher risk of Candida auris is important too. The lead author of the recent CDC's study spoke to ICT's sister brand for further insights on the threat.

Dapivirine Vaginal Ring is a form of HIV prevention in cisgender women during pregnancy approved in several African countries and recommended by the WHO.

These treatments were reviewed in a real-world application to evaluate their effectiveness in preventing recurrences.

Because of negative connotations and stigma associated with the term "monkeypox," WHO will fade out the term and use "mpox" in its place.

No new safety concerns with this COVID-19 vaccine were reported.

Respiratory syncytial virus (RSV) can be deadly for newborns and young infants. The newest information from Pfizer about its RSCpreF investigational vaccine is promising for new mothers and infants through the first 90 days of life.

The Clostridioides difficile Health-related Quality-of-Life Questionnaire responses demonstrated patients handled the situation better with specific investigational treatments.

With this declaration the United States is put on a list of countries circulating the viruses, specifically noted in Rockland County, NY, where the vaccination rate is low and surrounding areas.

The declaration will allow more funds for control of and resources for the disease.

With these declarations, the areas can use funds to help with preparedness and response to prevent the further spread of the disease.

Moderna has filed for the first FDA Emergency Use Authorization for this age group.

Masking during airline travel was halted yesterday by a federal judge, while other places, like Philadelphia, have re-implemented masking mandates.

The FDA authorized a second booster for both Pfizer and Moderna vaccination recipients 4 months after first booster shot.

The dose is half the antigen amount for adults but with similar amount of titers.

The FDA approved the Moderna vaccine as a 2-dose primary series for persons 18 years of age and older earlier this year.